Evaluation of Ocular Lens Proteins in Cataract From Individuals With Down Syndrome

Cataract Clinical Trial

Official title:

Evaluation of Ocular Lens Proteins in Cataract From Individuals With Down Syndrome

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03778528
• Other study ID #: 17-0372
• Status: Terminated
• Start date: May 30, 2018
• Est. completion date: July 1, 2020

Study information

• Verified date: July 2020
• Source: University of Colorado, Denver
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study involves the collection ocular lens tissue from individuals with Down syndrome and age-matched controls at the time of cataract surgery.

Description:

Individuals with Down syndrome have an increased rate of cataract. The reason for this increase is unclear. Normally, once cataracts become a significant impairment, an ophthalmologist will determine when cataract surgery should be performed. When this surgery is performed, cataractous tissues are cut out and discarded with medical waste. In this study, these tissue will be collected and protein analysis performed to determine what changes in different proteins are found in Down syndrome lenses as compared to normal cataractous lenses.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 1
• Est. completion date: July 1, 2020
• Est. primary completion date: July 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Month to 18 Years

Eligibility

Inclusion Criteria:

• Undergoing cataract surgery for lens extraction.

Exclusion Criteria:

• Known genetic cause other than Down syndrome causing cataract.

Related Conditions & MeSH terms

• Cataract
• Down Syndrome
• Syndrome

Intervention

Procedure:
• cataract surgery
tissue collection.

Locations

Country	Name	City	State
United States	Children's Hospital of Colorado	Aurora	Colorado

Sponsors (2)

Lead Sponsor	Collaborator
University of Colorado, Denver	Children's Hospital Colorado

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in protein composition	western blot analysis of proteins from cataractous tissue	one week after collection of tissue